FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2515-2517 December 13, 2007 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Corwin, H. L. PubMed Citation

To the Editor: Corwin et al. (Sept. 6 issue)¹ report that the use of epoetin alfa in critically ill patients does not reduce the incidence of red-cell transfusion but may reduce mortality among patients with trauma. However, the drug was given subcutaneously. It is well known that skin perfusion is impaired in patients with critical illness. Did the investigators conduct a pharmacokinetic evaluation in a subgroup to ensure adequate erythropoietin absorption? In addition, a relatively large erythropoietin dose was used in the study. Such a large dose could be associated with endothelial dysfunction, a proinflammatory state,² and increased thrombogenicity by . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.